Sharemaestro Newsreel

Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund

Point72 Asset Management and its related entities, including Point72 Capital Advisors, Inc. and Steven A. Cohen, have reported a beneficial ownership of 1,993,837 shares of Janux Therapeutics (JANX) common stock, representing 3.3% of the outstanding class as of June 30, 2026. This stake is …

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD

Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, …

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved …

Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition

Curis: Q2 Earnings Snapshot

Curis Inc. (CRIS) reported a second-quarter loss of $8.6 million, which translates to a loss of $4.02 per share. This information was generated by Automated Insights using data from Zacks Investment Research.

Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside

Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …

Satellos Bioscience (MSLE) enters $50M at-the-market share deal

Satellos Bioscience Inc. (MSLE) has established an at-the-market (ATM) equity offering program, allowing it to sell up to $50 million of its common shares through Leerink Partners LLC. This program operates under an existing shelf registration of up to $300 million and provides Satellos …

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., August 14, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate …

ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake

Point72 entities, including Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a 7.6% beneficial stake in Atara Biotherapeutics (ATRA). This stake, totaling 687,718 shares of common stock, is held by Point72 Associates, LLC, an investment fund managed by …

Baker Bros. cuts Cerus Corporation (CERS) position to 3.2% ownership stake

Baker Bros. Advisors LP and related reporting persons have filed an Amendment No. 13 indicating a reduction in their beneficial ownership of Cerus Corporation (CERS) common stock to 3.2%. This ownership comprises 6,395,431 shares held by Baker Brothers Life Sciences, L.P. and 667, L.P., …

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

This article announces that QIAGEN N.V. has received a notification from the AFM (the Netherlands Authority For the Financial Markets) regarding a voting rights announcement. Wellington Management Group LLP reported a transaction on August 12, 2026, indicating they hold 4.96% of the voting rights …

Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing

Femasys Inc. (NASDAQ: FEMY) reported a narrowed net loss for the first half of 2026, totaling $3,622,995, a significant improvement from $10,482,761 in the prior-year period. The company also announced the completion of a $30 million private placement, which is expected to strengthen its …

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss

Jasper Therapeutics (JSPR) announced a net loss of $2.8 million for the second quarter ended June 30, 2026. The company recently acquired Kira Pharmaceuticals, raising approximately $132 million, and anticipates releasing interim data and making regulatory filings for its expanded pipeline assets in late …

WAY (NASDAQ: WAY) files to sell 518,237 shares valued at $12.98M

Waystar Holding Corp. (NASDAQ: WAY) has filed a Form 144 to sell 518,237 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $12.98 million. The shares are related to option exercises under a registered …

Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A

Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has reported a beneficial ownership of 4.95% in Q32 Bio Inc. (QTTB) as of June 30, 2026. This stake consists of 1,173,396 shares, representing shared voting and dispositive power over the …

Rubric Capital discloses 6.56% Ardelyx (ARDX) stake totaling 16.2M shares

Rubric Capital Management LP and David Rosen have reported a 6.56% passive ownership stake in Ardelyx, Inc., amounting to 16,202,700 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, with Rubric Capital Master Fund LP …

Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with …

MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT)

MPM BioImpact LLC has disclosed an amended Schedule 13G filing, reporting a beneficial ownership of 18,331,420 Ordinary Shares in DBV Technologies S.A. This represents a 6.2% stake in the company, with MPM BioImpact LLC holding sole voting and dispositive power over these shares. The …

Boundless Bio (BOLD): Citadel entities and Ken Griffin report 0.6% ownership

Citadel-related entities and Ken Griffin have filed an amended Schedule 13G/A, disclosing a 0.6% beneficial ownership in Boundless Bio (BOLD) common stock. This filing indicates that Citadel Securities LLC holds 65,617 shares, while Citadel Securities Group LP, Citadel Securities GP LLC, and Ken Griffin …

Corcept Therapeutics (CORT) CBO reports 17,530-share stock gifts and trust holdings

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions involving 17,530 shares of the company's common stock on August 12, 2026. These transactions included a direct gift disposition of 11,530 shares and gifts of 3,000 shares each to two …

Profound Medical CFO Steps Down; Controller Takes Interim Role

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced a management change, with Matthew Sobczyk, formerly Corporate Controller, promoted to Interim Chief Financial Officer. He succeeds Rashed Dewan, who has stepped down but will remain on a short-term consulting contract to ensure a smooth transition. …

Quanterix Corp (QTRX) director-linked trusts buy 99,400 shares in open market

Quanterix Corp (QTRX) director William P. Donnelly, through trusts, indirectly purchased a total of 99,400 common shares in open-market transactions on August 12 and 13, 2026. The purchases were made at weighted average prices of $2.75 and $2.93 per share, respectively, totaling approximately $286,000. …

GridAI Technologies Corp. (GRDX) uses Rule 12b-25 for brief Q2 10-Q delay

Cardiff Oncology (CRDF) asks investors to double authorized common shares

Cardiff Oncology (CRDF) is seeking stockholder approval to significantly increase its authorized capital stock, specifically doubling its common stock from 150 million to 300 million shares. This move aims to provide the company with greater flexibility for future financings, strategic transactions, equity incentives, and …

Achieve Life Sciences (ACHV) launches $150M at-the-market stock program

Achieve Life Sciences (ACHV) has established a $150 million at-the-market (ATM) equity offering program with Jefferies LLC as the sales agent. The company plans to sell common stock periodically, with net proceeds intended for the commercialization of cytisinicline, funding a Phase 3 clinical trial …

Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise

Jeremy Hayden, an insider at Sight Sciences (SGHT), filed a Form 144 indicating his intent to sell 48,000 shares of common stock on August 14, 2026, following a stock option exercise. The planned sale has an aggregate market value of $395,878.84. This filing also …

Warby Parker (WRBY) Is Down 13.5% After Returning To Profitability And Reaffirming 2026 Revenue Guidance

Warby Parker (WRBY) reported a return to profitability in Q2 2026 with net income of US$4.64 million and reaffirmed its full-year 2026 revenue guidance of US$959 million to US$976 million. Despite these positive financial results, the stock is down 13.5%. The company's investment narrative …

Warby Parker (WRBY) co-founder Neil Blumenthal reports 8.25M-share, 7.2% stake

Warby Parker co-founder Neil H. Blumenthal has filed an amended Schedule 13G, disclosing beneficial ownership of 8,245,050 shares of Warby Parker Inc. Class A Common Stock, which represents a 7.2% stake in the company as of June 30, 2026. This ownership includes direct holdings, …

Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing

Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, have disclosed a 9.69% ownership stake in ADC Therapeutics SA (ADCT) via a 13G filing. As of June 30, 2026, they beneficially own 12,326,184 common shares, held through funds and …

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants

Vivo funds have disclosed beneficial ownership of 9.99% stakes in SAB Biotherapeutics (SABS) through various entities, including Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund. These stakes comprise common stock, Series B Preferred Stock, and warrants, with built-in blocking provisions ensuring that ownership …

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS)

Commodore Capital and its related entities have disclosed an 8.95 million share beneficial ownership in SAB Biotherapeutics (SABS), representing a 9.9% stake as of June 30, 2026. This position includes common shares, shares convertible from Series B Preferred Stock, and shares from Tranche 1 …

Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M

Organon (OGN): Pentwater Capital discloses 18.1M-share, 6.9% ownership stake

Pentwater Capital Management LP and Matthew Halbower have disclosed a passive ownership stake of 6.9% in Organon & Co., totaling 18,100,000 shares. This is based on 262,609,433 shares outstanding as of June 15, 2026. The shares are held by investment funds advised by Pentwater, …

MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock

MPM BioImpact LLC has filed an Amendment No. 2 to a Schedule 13G, disclosing a beneficial ownership of 1,299,046 shares of Context Therapeutics Inc. (CNTX) common stock, which represents 1.4% of the outstanding class. The firm holds sole voting and dispositive power over these …